ABT-510 in Treating Patients With Metastatic Melanoma
Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: ABT-510 may stop the growth of melanoma by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying how well giving ABT-510 works in treating patients
with metastatic melanoma.